Oracea (40mg doxycycline)

Oracea is a once per day 40mg (30mg immediate release and 10mg delayed release) doxycycline treatment for the papules and pustles of rosacea. Galderma promote Oracea as superior to 50mg a day of generic doxycycline because Oracea is a low enough dose to be promoted as an `anti-inflamatory only’ treatment and not suffering from potential problems of higher doses of antibiotics.

Be sure to checkout the Oracea User Reviews.

Recent Rosacea Blog Posts

How much does Galderma earn each year from Oracea sales ? Well the actual amount is not published, but in September 2011 court proceedings we learnt that Mylan Pharmaceuticals projected sales of $260m in 2011 for Oracea. The parent company of Galderma, L’Oreal does not publish Oracea sales figures, so this press release is as […]

Continue Reading

Oracea is Not an Antibiotic, Apparently

This claim from the Oracea web site caught my eye. Oracea is NOT an antibiotic. A bit of poetic marketing license perhaps? Oracea is a 40mg dose of the antibiotic doxycycline, which is a member of the tetracycline family. 30mg of the dose of doxycycline is immediate release, and 10 mg is locked inside a […]

Continue Reading

Amneal Pharmaceuticals joins the Generic Oracea War

News today of yet another company in the courts fighting against Galderma for the right to make Generic Oracea. Amneal Pharmaceuticals, based in Gujarat, India, a producer of generic pharmaceuticals, has submitted an Abbreviated New Drug Application to the FDA. By doing so, Amneal Pharmaecuticals are seeking permission to market delayed release doxycycline 40mg for […]

Continue Reading

Galderma wanting to show Oracea Maintains Rosacea Remission

A recently posted proposed Clinical Trial has me thinking that Galderma wants to be able to market Oracea as a product to Maintain Rosacea Remission. First Some History In 1998, Archives of Dermatology published a much quoted paper Topical Metronidazole Maintains Remissions of Rosacea. (the PDF of the full paper is available online). The premise […]

Continue Reading

An interesting note from the detailed interim judgement in the ongoing patent dispute between Galderma and Mylan. As part of the proceedings Mylan looked at the on-going Oracea sales and projected that Galderma can expect to receive around $260 million in 2011. MYLAN PHARMACEUTICALS INC., v.  GALDERMA LABORATORIES, L.P.; et. al. Mylan projected that Oracea’s […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.